What Is Anastrozole (Arimidex)? How Does It Work?
In this article
The Gold Standard in Hormone-Positive Breast Cancer: Anastrozole
One of the cornerstones of hormonal therapy in breast cancer treatment, Anastrozole (Arimidex®), is a potent aromatase inhibitor that prevents tumor growth by suppressing estrogen production, particularly in postmenopausal women (after menopause). It is an agent with proven success in reducing recurrence risk in adjuvant treatment.
Drug Profile
- Trade Name: Arimidex® (and equivalents)
- Active Ingredient: Anastrozole
- Class: Nonsteroidal Aromatase Inhibitor (Third Generation)
- Route of Administration: Oral Tablet (By Mouth)
- Manufacturer: AstraZeneca (Original manufacturer)
- Authorization: Authorized in Türkiye.
- Payment: Included on the SGK reimbursement list.
- Reimbursement Conditions: For patients diagnosed with hormone receptor-positive, postmenopausal breast cancer, based on a specialist physician’s report, the cost is reimbursed.
- Price: For 1 mg 28 Tablets, approximately 450 - 550 TL (Prices vary according to current exchange rates and lists).
Approved Indications
- Early-Stage Breast Cancer: Adjuvant (protective) treatment of hormone receptor-positive early-stage breast cancer in postmenopausal women.
- Advanced/Metastatic Breast Cancer: First-line treatment of advanced breast cancer in postmenopausal women.
- Switching After Tamoxifen: As continuation of treatment in patients previously treated with tamoxifen.
Clinical Importance and History
Anastrozole becoming standard care is based on one of the most comprehensive studies in oncology:
This landmark study demonstrated that Anastrozole was more effective than Tamoxifen in preventing recurrence and that some serious adverse effects, such as uterine cancer, were less common in the Anastrozole group. With this result, it became the first-choice treatment in postmenopausal women.
What Is Anastrozole and Its Molecular Mechanism of Action?
Anastrozole, which radically reduces the amount of estrogen in the body, is a selective aromatase inhibitor. However, its effect differs critically according to menopausal status.
🔬 How It Works at the Molecular Level
In postmenopausal women, estrogen is no longer produced in the ovaries. Instead, androgens released by the adrenal glands are converted into estrogen by the aromatase enzyme in fat and muscle tissue.
- 1. Enzyme Blockade: Anastrozole binds to the aromatase enzyme and stops its function. This means that androgens “cannot be converted” into estrogen.
- 2. Fuel-Cutting Strategy: Hormone-sensitive breast cancer cells use estrogen as a “fuel” to grow. Anastrozole starves cancer cells by reducing blood estrogen levels by more than %80.
- 3. Selectivity: Anastrozole is highly selective; it does not interfere with adrenal steroid production (cortisol, aldosterone, etc.), focusing only on estrogen synthesis.
Administration and Dosage
Taking Anastrozole is very simple but requires discipline.
- Standard Dose: A 1 mg tablet once daily.
- Timing: It can be taken with or without food. Taking it at the same time every day is recommended.
- Duration: In adjuvant treatment, it is generally used for 5 years (up to 10 years in some high-risk cases).
Adverse Effects and Their Management
The systemic decrease in estrogen leads to menopause-like symptoms:
- Joint and Muscle Pain (Arthralgia): This is the most common adverse effect. It is managed with exercise and simple painkillers on a doctor’s recommendation.
- Loss of Bone Density: Low estrogen can lead to bone loss (osteoporosis). Calcium/vitamin D supplementation and regular bone density measurement (DEXA) are essential.
- Hot Flashes: Sudden sweating and a sensation of heat similar to menopause.
- Vaginal Dryness: It may affect sexual health.
- Fatigue and Mood Changes: Mild depressive symptoms or tiredness may occur.
Special Situations and Warnings
- Premenopausal Use: Anastrozole alone is not effective in premenopausal women (it may even stimulate the ovaries). If used during this period, it must be combined with a drug that suppresses ovarian function (an LHRH analogue).
- Liver/Kidneys: It should be used cautiously in cases of severe insufficiency.
- Cholesterol: A mild increase in cholesterol levels may be observed in some patients; routine monitoring is recommended.
References
- Arimidex (anastrozole) FDA Prescribing Information.
- Baum M, et al. Anastrozole alone or in combination with tamoxifen (ATAC) trial. The Lancet. 2002.
- Cuzick J, et al. Long-term results of the ATAC trial. Lancet Oncol. 2010.
- Republic of Türkiye Ministry of Health, Arimidex Summary of Product Characteristics (KÜB).
Sources
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Lancet. 2002.
2. Boccardo F, Rubagotti A, Puntoni M, et al.
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
J Clin Oncol. 2005.
3. Nabholtz JM, Buzdar A, Pollak M, et al.
Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial.
J Clin Oncol 2000
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.